NCT00772915 · REGISTRY CONDITION SEARCH

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2020-01-18

RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating patients with newly diagnosed multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Progression-free Survival (PFS) Rate at 12 Months

→

outcome · POSTED

Confirmed Response Rate

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Newly diagnosed multiple myeloma, meeting the following criteria: * Symptomatic disease * Previously untreated disease * Measurable or evaluable disease, defined by ≥ 1 of the following: * Serum monoclonal protein ≥ 1.0 g/dL * Monoclonal protein \> 200 mg by 24-hour urine electrophoresis * Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa:lambda free light chain ratio * Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease) * Measurable soft tissue plasmacytoma, not previously radiated * No monoclonal gammopathy of unknown significance or asymptomatic myeloma PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-2 (PS 3 allowed if secondary to pain) * ANC ≥ 1,500/μL * Platelet count ≥ 75,000/μL * Creatinine ≤ 2.0 mg/dL * Total bilirubin ≤ 1.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use 2 effective forms of contraception 28 days prior to, during and 28 days after study treatment * Registered into the RevAssist® program and willing to comply with program requirements * Able to take prophylactic aspirin (325 mg/day) or warfarin or low molecular weight heparin * Willing to provide mandatory blood and bone marrow samples * Willing to return for follow up * No uncontrolled infection * No NYHA class III or IV heart failure * No active deep vein thrombosis that has not been therapeutically anticoagulated * No known hypersensitivity to thalidomide * No known HIV positivity * No known hepatitis type A, B, or C infection * No other prior active malignancy within the past 2 years, except currently treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast * No development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs PRIOR CONCURRENT THERAPY: * At least 3 weeks since prior radiotherapy for solitary plasmacytoma * More than 28 days since other prior experimental drug or therapy * Prior clarithromycin, DHEA, anakinra, pamidronate, or zoledronic acid allowed * No prior lenalidomide * No prior cytotoxic chemotherapy * No prior corticosteroids (≥ 160 mg of dexamethasone or equivalent) for this disease * Prior corticosteroid for nonmalignant disease allowed * Concurrent corticosteroids allowed (≤ 20 mg/day of prednisone or equivalent) * Concurrent palliative radiotherapy for bone pain or fracture allowed * No other concurrent anticancer agents or treatments
healthy Volunteers: false
maximum Age: 120 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles. Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.
intervention Names
Drug: dexamethasone
Drug: lenalidomide
label
Lenalidomide with On-Demand Dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
Lenalidomide with On-Demand Dexamethasone
description
Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression. If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle. If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly.
name
dexamethasone
type
DRUG
arm Group Labels
Lenalidomide with On-Demand Dexamethasone
description
25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles. Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described).
name
lenalidomide
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 39
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
PFS rate at 12 months is defined as the percentage of participants who are alive and progression-free at 12 months. Progression is exclusively defined as a patient with progressive disease while receiving treatment with lenalidomide in combination with dexamethasone. Progression was defined as any one or more of the following: An increase of 25% from lowest confirmed response in: * Serum M-component (absolute increase \>= 0.5g/dl) * Urine M-component (absolute increase \>= 200mg/24hour * Difference between involved and uninvolved Free Light Chain levels (absolute increase \>= 10mg/dl * Bone marrow plasma cell percentage (absolute increase of \>=10%)
measure
Progression-free Survival (PFS) Rate at 12 Months
time Frame
12 months from registration

secondary Outcomes

description
Confirmed response rate is defined as the percentage of participants who achieved a response that was confirmed on 2 consecutive evaluations during treatment * Complete Response(CR): Complete disappearance of M-protein from serum \& urine on immunofixation, normalization of Free Light Chain (FLC) ratio \& \<5% plasma cells in bone marrow (BM) * Very Good Partial Response(VGPR): \>=90% reduction in serum M-component; Urine M-Component \<100 mg per 24 hours; \<=5% plasma cells in BM * Partial Response PR): \>= 50% reduction in serum M-Component and/or Urine M-Component \>= 90% reduction or \<200 mg per 24 hours; or \>= 50% decrease in difference between involved and uninvolved FLC levels
measure
Confirmed Response Rate
time Frame
Up to 18 cycles from registration
description
OS was defined as the time from registration to death of any cause. Participants were followed for a maximum of 3 years from randomization. The median OS with 95% CI was estimated using the Kaplan Meier method
measure
Overall Survival (OS)
time Frame
Time from registration to death (up to 3 years)
description
PFS was defined as the time from registration to progression or death due to any cause. The median PFS with 95%CI was estimated using the Kaplan Meier method. Progression was defined as any one or more of the following:An increase of 25% from lowest confirmed response in: * Serum M-component (absolute increase \>= 0.5g/dl) * Urine M-component (absolute increase \>= 200mg/24hour * Difference between involved and uninvolved Free Light Chain levels (absolute increase \>= 10mg/dl * Bone marrow plasma cell percentage (absolute increase of \>=10%)
measure
Progression-free Survival (PFS)
time Frame
Time from registration to progression or death (up to 3 years)
description
The number of participants who experienced toxicity (defined as at least one grade 3 or higher adverse event at least possibly related to treatment) is reported below.
measure
Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)
time Frame
Duration on treatment (up to 18 cycles from registration)

Full study description

brief Summary: RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating patients with newly diagnosed multiple myeloma.
detailed Description: OBJECTIVES: Primary * To assess the progression-free survival at 1 year in patients with newly diagnosed symptomatic multiple myeloma treated with lenalidomide alone or in combination with dexamethasone added for disease progression or lack or partial response. Secondary * To assess the response rate of this regimen in these patients. * To assess the toxicity of this regimen in these patients. Tertiary * To examine the effect of lenalidomide alone on tumor specific immunity and global parameters of immune function. * To examine the effect of dexamethasone addition in patients requiring steroids. * To correlate changes in parameters of immune response and measures of disease response. * To examine the antiangiogenic activity of lenalidomide alone and in combination with dexamethasone. * To examine the effect of lenalidomide alone on tumor cell survival and proliferation. OUTLINE: Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of second disease progression or unacceptable toxicity. Beginning in course 4, patients experiencing stable or progressive disease also receive concurrent oral dexamethasone once daily on days 1, 8, 15, and 22 and for all subsequent courses. Blood and bone marrow samples are collected periodically for pharmacological and correlative studies. Samples are analyzed for parameters of immune activation, cell proliferation and apoptosis, and circulating tumor cells and endothelial cells via flow cytometry; global impact of therapy on immune cell subsets via immunophenotype analysis; and angiogenesis via CD34 staining. After completion of study therapy, patients are followed periodically for up to 2 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-12d95a86edfa94f8e756
requested nct id
NCT00772915
primary nct id
NCT00772915
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
53b1657ceddece0c5bb7eb679daa1f45d133361950fd45d5075872bd70d87b19
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-12d95a86edfa94f8e756
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00772915
occurrences
context exact
NCT00772915
end
11
exact text
NCT00772915
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/773/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
729e48be94732adbe3d496c4af23a9450f2644e97c18f382e41a58f13762edcf
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice